Ignite Creation Date:
2024-05-05 @ 5:02 PM
Last Modification Date:
2024-10-26 @ 9:27 AM
Study NCT ID:
NCT00372307
Status:
COMPLETED
Last Update Posted:
2007-12-28
First Post:
2006-09-04
Brief Title:
Efficacy and Safety of Pimecrolimus for the Treatment of Vitiligo Vulgaris
Sponsor:
University Hospital Ghent
Organization:
University Hospital Ghent
Study Overview
Official Title:
Efficacy and Safety of Pimecrolimus for the Treatment of Vitiligo Vulgaris
Status:
COMPLETED
Status Verified Date:
2007-12
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Patients with vitiligo vulgaris are treated with Pimecrolimus twice a day during 6 months After a baseline visit patient returns for a control visit after 3 and 6 months of treatment One reference lesion is clinically evaluated with pictures
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None